methotrexate has been researched along with Sclerosis, Systemic in 98 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (14.29) | 18.7374 |
| 1990's | 13 (13.27) | 18.2507 |
| 2000's | 30 (30.61) | 29.6817 |
| 2010's | 29 (29.59) | 24.3611 |
| 2020's | 12 (12.24) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, L; Cheng, Y; Jiang, Z; Lin, C; Ren, G; Shen, J; Shen, Y; Wan, W; Xu, W; Zhu, X; Zou, H | 1 |
| Kayser, C; Victória de Oliveira Martins, L | 1 |
| Damjanov, N; Jelovac, M; Kotur, N; Pavlovic, D; Pavlovic, S; Ristivojevic, B; Spasovski, V; Zukic, B | 1 |
| De, D; Handa, S; Kaushik, A; Mahajan, R | 1 |
| Tirelli, F; Zulian, F | 1 |
| Assassi, S; Bernstein, EJ; Castelino, FV; Clements, PJ; Domsic, RT; Elashoff, RM; Frech, T; Furst, DE; Goldin, J; Gordon, JK; Hant, FN; Hinchcliff, M; Khanna, D; Li, N; Mayes, MD; Roth, MD; Rünger, D; Shah, AA; Shanmugam, VK; Steen, VD; Tashkin, DP; Volkmann, ER; Ying, J | 1 |
| Buckley, M; Ede, KC; Edelheit, B; Ishaq, SS; Li, SC; Liu, C; Rabinovich, CE; Torok, KS | 1 |
| Wells, AU | 1 |
| Hudowenz, O; Klemm, P; Lange, U; Mueller-Ladner, U | 1 |
| Batalov, AZ; Batalov, ZA; Karalilova, RV; Matucci-Cerinic, M; Sapundzhieva, TL | 1 |
| Arida, A; Bournia, VK; Panopoulos, ST; Sfikakis, PP; Tektonidou, MG | 1 |
| Béhal, H; Duhamel, A; Faivre, JB; Hachulla, AL; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Le Gouellec, N; Matran, R; Morell-Dubois, S; Perez, T; Remy-Jardin, M; Sobanski, V | 1 |
| Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Sulli, A | 1 |
| Adler, S; Allanore, Y; Czirják, L; DelGaldo, F; Denton, CP; Distler, O; Frerix, M; Huscher, D; Matucci-Cerinic, M; Mueller-Ladner, U; Riemekasten, G; Siegert, E; Tarner, IH; Valentini, G; Villiger, PM; Walker, UA | 1 |
| Zulian, F | 1 |
| Fernández-Codina, A; Pope, JE; Walker, KM | 1 |
| Bershow, A; Crowson, AN; Lee, KR | 1 |
| Pan, L; Wang, Q; Xia, JX; Yang, QR; Zheng, JN; Zhu, GQ | 1 |
| Andrews, T; Becker, ML; Dedeoglu, F; Feldman, BM; Ferguson, PJ; Fuhlbrigge, RC; Higgins, GC; Hong, S; Ibarra, MF; Laxer, RM; Li, SC; Mason, T; Pope, E; Punaro, M; Rabinovich, CE; Stewart, K; Torok, KS | 1 |
| Abdo, MS; Gaber, SM; Mohammed, RH; Raslan, HM | 1 |
| Cuffaro, G; Sperotto, F; Zulian, F | 1 |
| Ishikawa, O; Motegi, S | 1 |
| Foeldvari, I | 1 |
| Bellando-Randone, S; Cappelli, S; Guiducci, S; Matucci-Cerinic, M | 1 |
| Akiyama, M; Muro, Y; Sugiura, K; Tanahashi, K | 1 |
| Feld, J; Shupak, A; Zisman, D | 1 |
| Furst, DE; Volkmann, ER | 1 |
| Bi, XD; Bian, H; Han, L; Hu, JL; Mao, BY; Yuan, M | 1 |
| Brusselle, G; Cutolo, M; DE Keyser, F; DE Pauw, M; Decuman, S; Deschepper, E; Melsens, K; Piette, Y; Pizzorni, C; Riccieri, V; Ruaro, B; Smith, V; Sulli, A; Vandecasteele, E | 1 |
| Rajapakse, C | 1 |
| Cerinic, MM; Valentini, G | 1 |
| Afsar, FS; Christen-Zaech, S; Hakim, MD; Paller, AS | 1 |
| Rudnicka, L; Sicińska, J | 1 |
| Lee, P; Low, AH | 1 |
| Feldman, BM; Johnson, SR; Pope, JE; Tomlinson, GA | 1 |
| Bournia, VK; Gershwin, ME; Moutsopoulos, HM; Selmi, C; Vlachoyiannopoulos, PG | 1 |
| Dwyer, N; Jones, G; Kilpatrick, D | 1 |
| Enk, A; Gholam, P; Hartmann, M; Sehr, T | 1 |
| Denton, CP; Quillinan, NP | 1 |
| Wimmersberger, Y; Zuercher, D | 1 |
| Isik, A; Koca, SS; Ozercan, IH; Ozgen, M | 1 |
| de Souza, CB; Ferriani, VP; Pileggi, GS | 1 |
| Olesińska, M; Wiesik-Szewczyk, E | 1 |
| Bau, V; Gahr, M; Hammermann, J; Hedrich, CM; Leszczynska, A | 1 |
| Pope, J; Walker, KM | 1 |
| Choi, YJ; Kim, HO; Kim, HS; Lee, JY; Park, YM | 1 |
| Gutmacher, Z; Levin, L; Teich, S; Zigdon, H | 1 |
| Baszis, K; Becker, M; Campillo, S; Cartwright, V; Cidon, M; Dedeoglu, F; Ferguson, PJ; Fuhlbrigge, RC; Higgins, GC; Hong, S; Ilowite, NT; Inman, CJ; Jacobe, HT; Jerath, R; Lasky, A; Laxer, RM; Li, SC; O'Neil, KM; Pope, E; Rabinovich, CE; Torok, KS; Vora, S; Wallace, CA; Zeft, A | 1 |
| Beyer, C; Dees, C; Distler, A; Distler, JH; Distler, O; Gelse, K; Khodzhigorova, A; Lang, V; Schett, G; Schneider, H | 1 |
| Lebeaux, D; Sène, D | 1 |
| Alonso, S; Alperi, M; Arboleya, L; Fernández-Serna, M; Queiro, R | 1 |
| Acar, P; Bodemer, C; Bonnet, D; Fournet, JC; Le Bidois, J; Ouachée-Chardin, M; Prieur, AM; Quartier, P | 1 |
| Athreya, BH | 1 |
| Lehman, TJ; Rosenkranz, ME | 1 |
| Meissner, T | 1 |
| Chwalińska-Sadowska, H; Mielnik, P; Prochorec-Sobieszek, M; Wagner, T | 1 |
| Alam, MR; Das, SN; Haq, SA; Islam, N; Khan, GK; Rahim, A; Rahman, MH; Rahman, S; Sutradhar, SR | 1 |
| Bargagli, E; Bellisai, F; Galeazzi, M; Rottoli, P; Volterrani, L | 1 |
| Cozzi, F; Favaro, M; Marotta, H; Ostuni, PA; Sfriso, P; Todesco, S | 1 |
| Furst, DE; Georges, GE; Henstorf, G; Langston, AA; Lee, J; McSweeney, PA; Nash, RA; Nelson, JL; Shulman, H; Storb, R; Sullivan, KM; Wener, M | 1 |
| van den Hoogen, FH | 2 |
| Kapoor, A; Khaitan, BK; Krishna Sumanth, M; Sharma, VK; Tejasvi, T | 1 |
| Szekanecz, Z; Tamási, L | 1 |
| Barry, J; Moktar, A; Murphy, GM; Ridge, CA | 1 |
| Alkassab, F | 1 |
| Baron, M; Bellamy, N; Campbell, J; Carette, S; Chalmers, I; Dales, P; Hanly, J; Kaminska, EA; Lee, P; Pope, JE | 1 |
| Boerbooms, AM; van de Putte, LB; van den Berg, WB; van den Hoogen, FH; van der Kraan, PM; van Lier, HJ | 1 |
| Boerbooms, AM; Rasker, JJ; Swaak, AJ; van de Putte, LB; van den Hoogen, FH; van Lier, HJ | 1 |
| Senécal, JL; Uthman, I; Vázquez-Abad, D | 1 |
| Cabral, D; Malleson, PN; Ortiz-Alvarez, O; Petty, RE; Prendiville, JS; Stringer, D | 1 |
| Wilke, WS | 1 |
| de Boo, T; de Jong, EM; Seyger, MM; van den Hoogen, FH | 1 |
| Cunningham, BB; Vierra, E | 1 |
| de Jong, EM; Seyger, MM; van de Kerkhof, PC; van den Hoogen, FH; van Vlijmen-Willems, IM | 1 |
| Baron, M; Bellamy, N; Carette, S; Catoggio, L; Chalmers, IM; Ellman, M; Furst, DE; Hong, P; Kaminska, E; Markland, J; O'Hanlon, D; Pope, JE; Seibold, JR; Sibley, J; Smith, CD | 1 |
| Carrier, S; Chen, TY; Zahran, AR | 1 |
| Steen, VD | 1 |
| Varga, J | 1 |
| Lehman, TJ | 1 |
| Ruszczak, Z | 1 |
| Schulze, P | 1 |
| Wigley, FM | 1 |
| Boerbooms, AM; Rasker, JJ; van de Putte, LB; van den Hoogen, FH; van Venrooij, WJ | 1 |
| Gross, WL; Reinhold-Keller, E; Schnabel, A; Wolff, HH | 1 |
| Medsger, TA | 1 |
| Boerbooms, AM; van de Putte, LB; van den Hoogen, FH | 1 |
| Paulus, HE | 1 |
| Moeschlin, S | 1 |
| Schwartz, RS; Skinner, MD | 1 |
| Barrière, H; Grolleau, JY; Welin, J | 1 |
| Kerl, H; Klein, G; Sandhofer, M | 1 |
| Arnett, FC; Stevens, MB; Whelton, JC; Zizic, TM | 1 |
| Górkiewicz, A; Kostanecki, W; Mazurkiewicz, W; Zborzil, J | 1 |
| Romiti, N | 1 |
| Schuppli, R | 2 |
| Civatte, J; Clauvel, JP; Danon, F; Degos, R | 1 |
27 review(s) available for methotrexate and Sclerosis, Systemic
| Article | Year |
|---|---|
Treatment of Inflammatory Arthritis in Systemic Sclerosis.
Topics: Arthralgia; Arthritis, Rheumatoid; Humans; Methotrexate; Quality of Life; Scleroderma, Systemic | 2023 |
Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history.
Topics: Adrenal Cortex Hormones; Biomarkers; Child; Humans; Methotrexate; Mycophenolic Acid; Phototherapy; Scleroderma, Localized; Scleroderma, Systemic | 2020 |
Treatment in Juvenile Scleroderma.
Topics: Child; Humans; Methotrexate; Mycophenolic Acid; Scleroderma, Localized; Scleroderma, Systemic | 2020 |
Scleroderma in children.
Topics: Child; Decision Making; Humans; Immunosuppressive Agents; Male; Methotrexate; Scleroderma, Localized; Scleroderma, Systemic | 2017 |
Scleroderma in children: an update.
Topics: Child; Early Diagnosis; Humans; Immunosuppressive Agents; Methotrexate; Scleroderma, Localized; Scleroderma, Systemic; Treatment Outcome | 2013 |
New developments in juvenile systemic and localized scleroderma.
Topics: Antibodies, Monoclonal, Humanized; Child; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Microscopic Angioscopy; Mycophenolic Acid; Scleroderma, Localized; Scleroderma, Systemic; Skin; Thermography; Tomography, Optical Coherence; Ultrasonography, Doppler; Uveitis | 2013 |
Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?
Topics: Azathioprine; Biological Products; Cyclophosphamide; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Remission Induction; Scleroderma, Systemic | 2014 |
Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches.
Topics: Animals; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Raynaud Disease; Scleroderma, Systemic; Treatment Failure | 2015 |
Anti-inflammatory: new trends in the treatment of the patient with systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as Topic; Cyclophosphamide; Endothelin A Receptor Antagonists; Europe; Humans; Immunosuppressive Agents; Methotrexate; Practice Guidelines as Topic; Scleroderma, Systemic | 2008 |
[Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
Topics: Adrenal Cortex Hormones; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Cytostatic Agents; Humans; Immunosuppressive Agents; Methotrexate; Musculoskeletal Diseases; Mycophenolic Acid; Scleroderma, Systemic | 2008 |
Recent advances in the treatment of systemic sclerosis.
Topics: Animals; Calcium Channel Blockers; Cell Differentiation; Clinical Trials as Topic; Cyclophosphamide; Fibroblasts; Fibrosis; Humans; Immunosuppressive Agents; Methotrexate; Scleroderma, Systemic; Signal Transduction; Vasodilator Agents; Ventricular Remodeling | 2009 |
Disease-modifying treatment in systemic sclerosis: current status.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantigens; Azathioprine; Collagen Type I; Connective Tissue Growth Factor; Cyclophosphamide; Evidence-Based Practice; Fibrosis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Plasmapheresis; Rituximab; Scleroderma, Systemic; Transforming Growth Factor beta; Transplantation, Autologous; Tumor Necrosis Factor-alpha | 2009 |
[Management of patients with systemic sclerosis].
Topics: Bone Marrow Transplantation; Cyclophosphamide; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Kidney Diseases; Lung Diseases, Interstitial; Methotrexate; Prognosis; Quality of Life; Raynaud Disease; Scleroderma, Systemic; Stem Cell Transplantation; Treatment Outcome | 2010 |
Eosinophilic fasciitis (Shulman disease).
Topics: Adrenal Cortex Hormones; Churg-Strauss Syndrome; Diagnosis, Differential; Edema; Eosinophilia; Eosinophilia-Myalgia Syndrome; Fasciitis; Humans; Magnetic Resonance Imaging; Methotrexate; Rare Diseases; Scleroderma, Localized; Scleroderma, Systemic; Skin Diseases | 2012 |
Dropped head syndrome in a patient with scleromyositis.
Topics: Drug Therapy, Combination; Humans; Male; Methotrexate; Middle Aged; Muscle Weakness; Myositis; Neck Muscles; Prednisone; Scleroderma, Systemic; Syndrome; Treatment Outcome | 2013 |
Juvenile scleroderma.
Topics: Adjuvants, Immunologic; Antirheumatic Agents; Child; Drug Therapy, Combination; Humans; Methotrexate; Scleroderma, Systemic; Vasodilator Agents | 2002 |
[Treatment of systemic sclerosis].
Topics: Cyclophosphamide; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Methotrexate; Penicillamine; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Vasodilator Agents | 2006 |
[Biological therapy of arthritis and systemic autoimmune diseases].
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; B-Lymphocytes; Biological Therapy; Dermatomyositis; Humans; Lupus Erythematosus, Systemic; Methotrexate; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome; Spondylitis, Ankylosing; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2007 |
Methotrexate use in miscellaneous inflammatory diseases.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Connective Tissue Diseases; Humans; Inflammation; Lupus Erythematosus, Systemic; Methotrexate; Myositis; Sarcoidosis; Scleroderma, Systemic; Still's Disease, Adult-Onset | 1997 |
Therapeutic interventions in systemic sclerosis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Cyclophosphamide; Humans; Methotrexate; Netherlands; Scleroderma, Systemic; Survival Rate; Treatment Outcome | 1998 |
Morphea and localized scleroderma in children.
Topics: Adrenal Cortex Hormones; Biomarkers; Calcitriol; Child; Dermatologic Agents; Humans; Immunosuppressive Agents; Methotrexate; Scleroderma, Localized; Scleroderma, Systemic; Skin; Ultraviolet Therapy | 1999 |
Treatment of systemic sclerosis.
Topics: Antirheumatic Agents; Cyclosporine; Drug Therapy, Combination; Humans; Interferons; Methotrexate; Middle Aged; Raynaud Disease; Scleroderma, Systemic | 2001 |
[Immunosuppressive agents for therapy of autoimmune diseases of the skin and of psoriasis].
Topics: Autoimmune Diseases; Dermatitis Herpetiformis; Dermatomyositis; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Methotrexate; Pemphigus; Polyarteritis Nodosa; Psoriasis; Pyoderma; Scleroderma, Systemic; Skin Diseases | 1977 |
[Indications and limits of long-term therapy with immunosuppressive (and cytostatic) agents in various chronic skin diseases].
Topics: Arthritis, Reactive; Azathioprine; Chronic Disease; Cyclophosphamide; Dermatomyositis; Humans; Immunosuppressive Agents; Impetigo; Long-Term Care; Lupus Erythematosus, Discoid; Methotrexate; Pemphigus; Penicillamine; Polyarteritis Nodosa; Prednisolone; Psoriasis; Pyoderma; Scleroderma, Systemic; Skin Diseases; Wissler's Syndrome | 1977 |
Treatment of systemic sclerosis.
Topics: Cyclosporine; Humans; Methotrexate; Penicillamine; Photochemotherapy; Raynaud Disease; Scleroderma, Systemic | 1992 |
Treatment of systemic sclerosis.
Topics: Humans; Interferon-gamma; Methotrexate; Retinoids; Scleroderma, Systemic | 1990 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid; Azathioprine; Blood Coagulation Disorders; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Cyclophosphamide; Dermatomyositis; Factor VIII; Hepatitis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mercaptopurine; Methotrexate; Prednisolone; Purpura, Thrombocytopenic; Scleroderma, Systemic | 1972 |
12 trial(s) available for methotrexate and Sclerosis, Systemic
| Article | Year |
|---|---|
Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Severity of Illness Index; Skin; Skin Ulcer; Ultrasonography | 2021 |
[Effect of Wenyang Huazhuo Tongluo Recipe on Peripheral Blood Thl7/Treg Cell Balance in Systemic Sclerosis Patients].
Topics: Drugs, Chinese Herbal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-10; Interleukin-17; Methotrexate; Peptide Fragments; Procollagen; Scleroderma, Systemic; T-Lymphocytes, Regulatory; Th17 Cells | 2015 |
Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
Topics: Adult; Antirheumatic Agents; Bayes Theorem; Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blind Method; Humans; Methotrexate; Outcome Assessment, Health Care; Placebos; Rare Diseases; Reproducibility of Results; Scleroderma, Systemic; Skin Diseases; Treatment Outcome | 2009 |
Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis, Juvenile; Chickenpox Vaccine; Child; Child, Preschool; Dermatomyositis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Injections, Subcutaneous; Male; Methotrexate; Scleroderma, Systemic; Vaccines, Attenuated; Young Adult | 2010 |
Placebo controlled trial of methotrexate in systemic sclerosis.
Topics: Adolescent; Adult; Antirheumatic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Respiratory Function Tests; Scleroderma, Systemic; Statistics, Nonparametric; Treatment Outcome | 2005 |
Evaluation of oral methotrexate in the treatment of systemic sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Immunosuppressive Agents; India; Male; Methotrexate; Middle Aged; Scleroderma, Systemic; Treatment Outcome | 2007 |
Variability of skin scores and clinical measurements in scleroderma.
Topics: Female; Humans; Male; Methotrexate; Middle Aged; Observer Variation; Reproducibility of Results; Scleroderma, Systemic; Skin; Treatment Outcome | 1995 |
Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
Topics: Adult; Aged; Antirheumatic Agents; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Scleroderma, Systemic; Severity of Illness Index; Time Factors; Treatment Outcome | 1996 |
Low-dose methotrexate in the treatment of widespread morphea.
Topics: Adult; Aged; Biomarkers; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Methotrexate; Middle Aged; Peptide Fragments; Procollagen; Prospective Studies; Scleroderma, Systemic; Skin; Statistics, Nonparametric; Time Factors | 1998 |
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Topics: Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Health Status; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Scleroderma, Systemic; Severity of Illness Index; Skin; Surveys and Questionnaires; Treatment Outcome | 2001 |
Methotrexate shows marginal clinical efficiency in early scleroderma.
Topics: Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Prospective Studies; Scleroderma, Systemic | 2002 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid; Azathioprine; Blood Coagulation Disorders; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Cyclophosphamide; Dermatomyositis; Factor VIII; Hepatitis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mercaptopurine; Methotrexate; Prednisolone; Purpura, Thrombocytopenic; Scleroderma, Systemic | 1972 |
60 other study(ies) available for methotrexate and Sclerosis, Systemic
| Article | Year |
|---|---|
Spontaneous tendon rupture in a patient with systemic sclerosis: a case report.
Topics: Female; Humans; Methotrexate; Middle Aged; Rupture, Spontaneous; Scleroderma, Systemic; Tendon Injuries; Tendons; Tenosynovitis | 2022 |
Can Pharmacogenetic Variants in
Topics: Azathioprine; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Scleroderma, Systemic | 2023 |
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.
Topics: Adult; Aged; beta 2-Microglobulin; Chemokine CCL19; Chemokine CCL8; Chemokine CXCL10; Chemokine CXCL9; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Observational Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type II; Scleroderma, Systemic; Vital Capacity | 2021 |
Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma.
Topics: Abatacept; Adolescent; Antirheumatic Agents; Child; Cohort Studies; Female; Humans; Male; Methotrexate; Mycophenolic Acid; Retrospective Studies; Scleroderma, Localized; Scleroderma, Systemic; Treatment Failure; Treatment Outcome | 2021 |
New insights into the treatment of CTD-ILD.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Connective Tissue Diseases; Disease Progression; Humans; Indoles; Interleukin-6; Lung Diseases, Interstitial; Methotrexate; Prevalence; Protein Kinase Inhibitors; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Vital Capacity | 2021 |
Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
Topics: Arthritis; Azetidines; Female; Humans; Immunoglobulins; Immunosuppressive Agents; Methotrexate; Middle Aged; Polymyositis; Purines; Pyrazoles; Scleroderma, Systemic; Sulfonamides | 2021 |
Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Topics: Adult; Antirheumatic Agents; Female; Humans; Interleukin-6; Methotrexate; Middle Aged; Rituximab; Scleroderma, Systemic; Treatment Outcome | 2022 |
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cyclophosphamide; Diffusion; Echocardiography; Female; Fingers; Follow-Up Studies; Humans; Hypertension, Pulmonary; Linear Models; Lung; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Pulmonary Diffusing Capacity; Respiratory Function Tests; Scleroderma, Systemic; Ulcer; Young Adult | 2017 |
Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis.
Topics: Bosentan; Female; Fingers; Humans; Iloprost; Lasers; Methotrexate; Microcirculation; Microscopic Angioscopy; Middle Aged; para-Aminobenzoates; Raynaud Disease; Scattering, Radiation; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tramadol; Treatment Outcome | 2017 |
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lung; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Precision Medicine; Respiratory Function Tests; Scleroderma, Systemic | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Calcium Channels; Cyclophosphamide; Endothelin Receptor Antagonists; Glucocorticoids; Humans; Hydroxychloroquine; Hypertension, Pulmonary; Immunosuppressive Agents; Kidney Diseases; Lung Diseases, Interstitial; Methotrexate; Mycophenolic Acid; Phosphodiesterase 5 Inhibitors; Prostaglandins; Raynaud Disease; Rituximab; Scleroderma, Systemic | 2018 |
Elephantiasis nostras verrucosa secondary to scleroderma.
Topics: Anti-Bacterial Agents; Bandages; Biopsy; Cephalexin; Dermatologic Agents; Doxepin; Elephantiasis; Female; Humans; Methotrexate; Middle Aged; Mupirocin; Mycophenolic Acid; PUVA Therapy; Scleroderma, Systemic; Skin; Skin Cream; Terfenadine; Treatment Outcome | 2019 |
Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Topics: Adult; Azathioprine; Bayes Theorem; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Scleroderma, Systemic; Treatment Outcome; Vital Capacity | 2020 |
Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Antirheumatic Agents; Child; Comparative Effectiveness Research; Drug Therapy, Combination; Feasibility Studies; Female; Glucocorticoids; Humans; Male; Methotrexate; Methylprednisolone; Pilot Projects; Prednisone; Prospective Studies; Rare Diseases; Scleroderma, Localized; Scleroderma, Systemic; Young Adult | 2019 |
Serum B-cell activating factor assessment in a population of Egyptian patients with systemic sclerosis.
Topics: Adolescent; Adult; B-Cell Activating Factor; Biomarkers; Case-Control Studies; Chi-Square Distribution; Cross-Sectional Studies; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunosuppressive Agents; Intestinal Pseudo-Obstruction; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Scleroderma, Systemic; Severity of Illness Index; Up-Regulation; Young Adult | 2013 |
Methotrexate-induced accelerated nodulosis in a patient with rheumatoid arthritis and scleroderma.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Receptors, Tumor Necrosis Factor; Rheumatoid Nodule; Risk Factors; Scleroderma, Systemic; Time Factors | 2014 |
Disappearance of circulating autoantibodies to RNA polymerase III in a patient with systemic sclerosis successfully treated with corticosteroid and methotrexate.
Topics: Aged; Autoantibodies; Drug Therapy, Combination; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Methotrexate; RNA Polymerase III; Scleroderma, Systemic | 2015 |
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arrhythmias, Cardiac; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Hearing Loss, Sensorineural; Humans; Labyrinth Diseases; Meniere Disease; Methotrexate; Monitoring, Immunologic; Prednisone; Scleroderma, Systemic | 2015 |
Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study.
Topics: Adult; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Methotrexate; Microcirculation; Microvessels; Middle Aged; Nails; Pilot Projects; Rituximab; Scleroderma, Systemic | 2016 |
Pharyngoesophageal dysphagia: an under recognised, potentially fatal, but very treatable feature of systemic sclerosis.
Topics: Aged; Deglutition Disorders; Endoscopy, Gastrointestinal; Female; Fluoroscopy; Humans; Male; Methotrexate; Middle Aged; Prednisone; Scleroderma, Systemic | 2016 |
Pediatric morphea (localized scleroderma): review of 136 patients.
Topics: Adolescent; Age of Onset; Antibodies, Antinuclear; Autoimmune Diseases; Child; Child, Preschool; Dermatologic Agents; Female; Humans; Infant; Male; Methotrexate; Prevalence; Retrospective Studies; Risk Factors; Scleroderma, Localized; Scleroderma, Systemic; Sex Factors; Skin; White People | 2008 |
Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis.
Topics: Adult; Humans; Immunosuppressive Agents; Methotrexate; Middle Aged; Scleroderma, Systemic | 2008 |
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Interactions; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Polypharmacy; Scleroderma, Systemic; Sulfonamides | 2009 |
Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Topics: Adult; Amlodipine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Fingers; Follow-Up Studies; Hand Dermatoses; Humans; Methotrexate; Receptor, Endothelin A; Risk Assessment; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Treatment Outcome | 2009 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves Disease; Humans; Hypertension, Pulmonary; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Proteinuria; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2009 |
Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
Topics: Animals; Antirheumatic Agents; Bleomycin; Disease Models, Animal; Fibrosis; Injections, Intraperitoneal; Methotrexate; Mice; Mice, Inbred BALB C; Scleroderma, Systemic; Skin; Treatment Outcome | 2010 |
Chorioretinitis in a 7-year-old African girl, probably related to JSSc resolving to methotrexate therapy.
Topics: Child; Chorioretinitis; Diagnosis, Differential; Female; Germany; Humans; Immunosuppressive Agents; Methotrexate; Ophthalmoscopes; Scleroderma, Systemic; Visual Acuity | 2011 |
Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.
Topics: Bosentan; Canada; Epoprostenol; Europe; Health Surveys; Humans; Hypertension, Pulmonary; Iloprost; Methotrexate; North America; Practice Guidelines as Topic; Scleroderma, Systemic; Skin Diseases; Societies, Medical; Sulfonamides; Treatment Outcome; Vascular Diseases | 2011 |
Case of juvenile localized scleroderma with joint sclerosis and Sjögren's syndrome in a child with precocious puberty.
Topics: Child; Female; Humans; Joint Diseases; Methotrexate; Methylprednisolone; Puberty, Precocious; Scleroderma, Localized; Scleroderma, Systemic; Sclerosis; Sjogren's Syndrome; Triptorelin Pamoate | 2011 |
Full-mouth rehabilitation using dental implants in a patient with scleroderma.
Topics: Alveolar Bone Loss; Dental Caries; Dental Implantation, Endosseous; Dental Implants; Dental Prosthesis, Implant-Supported; Denture Design; Denture, Complete; Esthetics, Dental; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Methotrexate; Middle Aged; Mouth Rehabilitation; Oral Hygiene; Periodontal Diseases; Scleroderma, Systemic; Steroids; Tooth Extraction | 2011 |
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
Topics: Adolescent; Consensus; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Methylprednisolone; Practice Guidelines as Topic; Program Development; Randomized Controlled Trials as Topic; Scleroderma, Localized; Scleroderma, Systemic; Treatment Outcome; Young Adult | 2012 |
Inhibition of sumoylation prevents experimental fibrosis.
Topics: Adolescent; Adult; Animals; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Knockdown Techniques; Humans; Immunosuppressive Agents; Keratinocytes; Male; Methotrexate; Mice; Middle Aged; Receptors, Transforming Growth Factor beta; RNA, Small Interfering; Scleroderma, Systemic; Signal Transduction; Skin; Smad3 Protein; SUMO-1 Protein; Sumoylation; Ubiquitin-Conjugating Enzymes; Young Adult | 2012 |
Severe cardiac involvement in children with systemic sclerosis and myositis.
Topics: Adolescent; Cardiomyopathies; Child; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male; Methotrexate; Polymyositis; Prednisone; Scleroderma, Systemic; Survival Rate; Treatment Outcome | 2002 |
Clinical trials for pediatric scleroderma.
Topics: Antirheumatic Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Humans; Methotrexate; Penicillamine; Scleroderma, Systemic | 2002 |
[New strategies against autoaggressive immune system. Is rheumatism to be healable soon?].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroscopy; Cells, Cultured; Chondrocytes; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Infliximab; Lupus Erythematosus, Systemic; Methotrexate; Rheumatic Diseases; Scleroderma, Systemic; Stem Cell Transplantation; Tumor Necrosis Factor-alpha | 2003 |
Mucosa-associated lymphoid tissue lymphoma (MALT) of salivary glands and scleroderma: a case report.
Topics: Adult; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lymphoma, B-Cell, Marginal Zone; Methotrexate; Parotid Neoplasms; Prednisone; Scleroderma, Systemic | 2004 |
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Comorbidity; Drug Therapy, Combination; Female; Fibrosis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Infliximab; Lung; Methotrexate; Middle Aged; Pulmonary Wedge Pressure; Respiratory Function Tests; Scleroderma, Systemic; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha | 2008 |
Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate.
Topics: Antihypertensive Agents; Arthritis; Bosentan; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2006 |
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Fibrosis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Methotrexate; Myeloablative Agonists; Scleroderma, Systemic; Skin; Transplantation Conditioning; Transplantation, Homologous | 2006 |
Photochemotherapy and methotrexate used to treat generalized cutaneous scleroderma.
Topics: Adolescent; Biopsy; Dermatologic Agents; Humans; Male; Methotrexate; PUVA Therapy; Scleroderma, Systemic | 2007 |
Overlap of systemic sclerosis and rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Hand; Humans; Immunoglobulin G; Methotrexate; Middle Aged; Radiography; Receptors, Tumor Necrosis Factor; Rheumatology; Scleroderma, Systemic; Treatment Outcome | 2007 |
Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture.
Topics: Adult; Aged; Cell Count; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Female; Fibroblasts; Glycosaminoglycans; Humans; Male; Methotrexate; Middle Aged; Scleroderma, Systemic; Skin | 1993 |
Distinctive features of idiopathic inflammatory myopathies in French Canadians.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Breast Neoplasms; Canada; Carcinoma; Carcinoma in Situ; Carcinoma, Squamous Cell; Creatine Kinase; Esophageal Neoplasms; Female; Follow-Up Studies; Histidine-tRNA Ligase; Humans; Longitudinal Studies; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Mixed Connective Tissue Disease; Nuclear Envelope; Polymyositis; Prednisone; Pulmonary Fibrosis; Retrospective Studies; Scleroderma, Systemic; Skin Neoplasms; Survival Analysis | 1996 |
Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Child, Preschool; Dermatologic Agents; Female; Humans; Intestinal Obstruction; Intestine, Small; Methotrexate; Penicillamine; Prednisone; Radiography; Scleroderma, Systemic; Skin; Stomach | 1997 |
Localized and systemic scleroderma show different histological responses to methotrexate therapy.
Topics: Adult; Dermatologic Agents; Female; Heparin; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Male; Mast Cells; Methotrexate; Middle Aged; Proteoglycans; Scleroderma, Localized; Scleroderma, Systemic; Tenascin; Treatment Outcome | 2001 |
Penile curvature associated with scleroderma.
Topics: Adult; Fibrosis; Humans; Male; Methotrexate; Penile Induration; Scleroderma, Systemic; Ultrasonography | 2001 |
Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope et al.
Topics: Antirheumatic Agents; Child, Preschool; Humans; Methotrexate; Scleroderma, Systemic | 2002 |
Low dose methotrexate treatment in systemic sclerosis.
Topics: Humans; Methotrexate; Pilot Projects; Scleroderma, Systemic | 1991 |
[Tryptophan-induced fasciitis-scleroderma-eosinophilia syndrome].
Topics: Aged; Creatine Kinase; Diagnosis, Differential; Eosinophilia; Fasciitis; Female; Fructose-Bisphosphate Aldolase; Glucocorticoids; Humans; Hydroxychloroquine; Methotrexate; Middle Aged; Scleroderma, Systemic; Skin; Syndrome; Time Factors; Tryptophan | 1991 |
Methotrexate treatment in scleroderma.
Topics: Aged; Female; Humans; Male; Methotrexate; Middle Aged; Scleroderma, Systemic | 1989 |
FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dimethyl Sulfoxide; Humans; Methotrexate; Scleroderma, Systemic | 1986 |
[Treatment of autoimmune diseases].
Topics: Adrenal Cortex Hormones; Aged; Anemia, Hemolytic, Autoimmune; Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; Blood Protein Disorders; Child, Preschool; Chloramphenicol; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Drug Synergism; Female; Hepatitis; Humans; Immunosuppressive Agents; Long-Term Care; Lupus Vulgaris; Male; Methotrexate; Middle Aged; Nephrosis, Lipoid; Pemphigus; Polyarteritis Nodosa; Postoperative Complications; Purpura, Thrombocytopenic; Scleroderma, Systemic; Transplantation, Homologous | 1971 |
[Scleroderma and Gougerot-Sjögren syndrome. Effect of methotrexate therapy].
Topics: Adult; Aged; Female; Humans; Methotrexate; Scleroderma, Systemic; Sjogren's Syndrome | 1973 |
[Treatment of "collagen and autoimmune" diseases (author's transl)].
Topics: Adolescent; Adult; Aminobenzoates; Azathioprine; Chloroquine; Cyclophosphamide; Dermatomyositis; Dextrans; Female; Humans; Indomethacin; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Norethindrone; Penicillamine; Pregnanes; Scleroderma, Localized; Scleroderma, Systemic | 1973 |
Methotrexate therapy in polymyositis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biopsy; Creatine Kinase; Dermatomyositis; Female; Fructose-Bisphosphate Aldolase; Humans; L-Lactate Dehydrogenase; Lung; Male; Methotrexate; Middle Aged; Muscular Diseases; Myositis; Pneumonia; Prednisone; Radiography; Scleroderma, Systemic | 1973 |
[Hair changes in immunosuppressive therapy].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Hair; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Scleroderma, Systemic; Skin Diseases; Vinblastine | 1971 |
[Use of antimetabolites in diseases of auto-aggression].
Topics: Adult; Aged; Autoimmune Diseases; Child, Preschool; Cortisone; Dermatomyositis; Female; Humans; Lupus Erythematosus, Systemic; Mercaptopurine; Methotrexate; Middle Aged; Scleroderma, Systemic | 1968 |
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mercaptopurine; Methotrexate; Papilloma; Pemphigus; Precancerous Conditions; Psoriasis; Scleroderma, Systemic; Skin Diseases; Skin Neoplasms; Virus Diseases | 1970 |
[Treatment of dermatologic lesions using immunosuppressive agents and cytostatics].
Topics: Antineoplastic Agents; Azathioprine; Dermatomyositis; Fluorouracil; Humans; Immunosuppressive Agents; Methotrexate; Pemphigus; Psoriasis; Scleroderma, Systemic; Skin Diseases; Skin Neoplasms | 1970 |
[Globulin anomalies in skin mucinosis].
Topics: Adult; Aged; Blood Protein Disorders; Diagnosis, Differential; Female; Humans; Immunoglobulin G; Immunoglobulins; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Myxedema; Scleroderma, Systemic; Serum Globulins; Skin Diseases | 1970 |